Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it has created a Clinical Advisory Board (“CAB”). The company has named world-renowned medical and clinical experts as the board’s first members. The purpose of the board is to provide expert guidance for Genprex’s novel gene therapy clinical development programs in cancer and diabetes. More specifically, CAB members will provide invaluable guidance and advise as Genprex advances its REQORSA(TM) (“REQORSA”) immunogene therapy program and its preclinical diabetes gene therapy program. Board members include the following: Michael Morse, MD, MHS, FACP; Col. George E. Peoples, MD, FACS; Andrew B. Becker, MD, PhD; and William E. Gannon, Jr., MD, MBA. Genprex also has entered into securities purchase agreements with two healthcare-dedicated institutional investors. Expected to close on or about Feb. 11, 2021, the agreements outline the purchase and sale of 4 million shares of GNPX common stock at a purchase price of $6.25 per share in a registered direct offering; the agreements are priced at-the-market under Nasdaq rules. “We are pleased to bring together this group of seasoned practitioners in the field of oncology and diabetes to guide and advise Genprex in advancing our clinical development programs,” said Genprex’s CEO Rodney Varner in the press release. “The Clinical Advisory Board’s experience in clinical trials of cancer and diabetes therapies, combined with their expertise in consulting with small and large biotechnology companies, is invaluable as our drug candidates progress into the clinic.”

To view the full press releases, visit https://ibn.fm/ALIpH and https://ibn.fm/J3TxJ

About Genprex Inc. 

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for REQORSA for NSCLC (“NSCLC”) in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR (“EFGR”) mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in Genprex Inc. GNPX, MissionIRNewsBreaks. Bookmark the permalink.

Comments are closed.